AbbVie wins FDA nod for Decnupaz for rare blood cancer indication
- Posted on May 28, 2026
- By Bing News
- 0 Views
- 1 min read
AbbVie wins FDA nod for Decnupaz for rare blood cancer indication
AbbVie ABBV announced the FDA approval of Decnupaz (pivekimab sunirine-pvzy) for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). The disease is an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval gives AbbVie its first antibody-drug conjugate (ADC) approved for a blood cancer and adds a new treatment option for a patient group with high unmet need. Decnupaz,...
